慢性乙型肝炎患者肝癌监测的成本效用分析:生物标志物策略与超声联合甲胎蛋白的比较
该研究采用Markov模型模拟慢性乙型肝炎队列,从社会视角评估USG+AFP、GAAD、GALAD、ASAP及不监测等策略的成本效用。结果显示每6个月ASAP最具成本效果,ICER为102,443泰铢/QALY(对比每12个月ASAP)和76,447泰铢/QALY(对比不监测);每6个月USG+AFP终身成本最高(166,253泰铢)。敏感性分析证实每6个月ASAP稳健,关键驱动因素包括生物标志物成本、HCC分期效用值和发病率。
要点
- 每6个月ASAP是慢性乙型肝炎患者最具成本效果的肝癌监测策略。
- 每6个月GAAD和GALAD虽QALY相似但因成本更高而被支配。
- 每6个月USG+AFP终身成本最高,达166,253泰铢。
核心结论
- 每6个月ASAP是慢性乙型肝炎患者最具成本效果的肝癌监测策略,尤其适合资源有限环境。
研究设计与样本
- 采用Markov模型模拟慢性乙型肝炎患者队列,评估USG+AFP、GAAD、GALAD、ASAP及不监测策略的成本效果。
- 分析采用社会视角和终身时间范围,计算每获得质量调整生命年(QALY)的增量成本效果比(ICER),单位为泰铢(THB)。
- 输入参数来源于文献和泰国医疗数据,并进行敏感性分析评估稳健性。
主要发现
- 每6个月ASAP对比每12个月ASAP的ICER为102,443泰铢(约2957美元)/QALY。
- 每6个月ASAP对比不监测的ICER为76,447泰铢(约2207美元)/QALY。
- 每6个月GAAD和GALAD达到相似QALY但因成本更高而被支配。
- 每6个月USG+AFP的终身成本最高,为166,253泰铢(约4800美元)。
- 敏感性分析证实每6个月ASAP稳健,关键驱动因素包括生物标志物成本、HCC分期效用值和发病率。
关键数值与推荐
- 每6个月ASAP对比每12个月ASAP的ICER为102,443泰铢(约2957美元)/QALY。
- 每6个月ASAP对比不监测的ICER为76,447泰铢(约2207美元)/QALY。
- 每6个月USG+AFP终身成本为166,253泰铢(约4800美元)。
临床怎么用
- 对慢性乙型肝炎患者,每6个月ASAP监测策略可优先考虑以改善结局并优化资源使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The standard surveillance for hepatocellular carcinoma (HCC) involves ultrasound (USG) with alpha-fetoprotein (AFP) every 6 months. However, limitations, such as restricted access, radiologist shortages, and uncertain cost-effectiveness, persist. AIMS: We assessed the cost-effectiveness of traditional and biomarker-based HCC surveillance strategies in patients with chronic hepatitis B (CHB). METHODS: A Markov model simulated a cohort of patients with CHB to evaluate the cost-effectiveness of various surveillance strategies: USG + AFP, GAAD, GALAD, ASAP, and no surveillance. Input parameters were sourced from literature and Thai healthcare data. The analysis adopted a societal perspective and lifetime horizon, calculating incremental cost-effectiveness ratios (ICERs) in Thai Baht (THB) per quality-adjusted life year (QALY) gained. Sensitivity analyses assessed robustness. RESULTS: ASAP every 6 months was the most cost-effective strategy, with ICERs of 102,443 THB (~2957 USD) per QALY versus ASAP every 12 months and 76,447 THB (~2207 USD) per QALY versus no surveillance. Although GAAD and GALAD every 6 months achieved similar QALYs, they were dominated due to higher costs. Annual surveillance improved cost-effectiveness but remained inferior to ASAP every 6 months. USG + AFP every 6 months incurred the highest lifetime cost (166,253 THB, ~4800 USD). Sensitivity analyses confirmed the robustness of ASAP every 6 months, with key drivers including biomarker costs, HCC stage utilities, and incidence rates. CONCLUSIONS: ASAP every 6 months is the most cost-effective HCC surveillance strategy for patients with CHB and may be particularly suitable for resource-limited settings. Biomarker-based surveillance should be prioritised to improve outcomes and optimise resource use.
引用
- Saeoui T, Kositamongkol C, Chantrakul R, et al. Cost-Utility Analysis of Biomarker-Based vs. USG + AFP Strategies for HCC Surveillance in Chronic Hepatitis B. Aliment Pharmacol Ther. 2025. PMID: 40985795. doi:10.1111/apt.70386
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。